Intra-BM transfusion of Angptl7 significantly accelerated AML progression in Id1-deficient recipient mice. (A-B) Id1^−/− recipient mice without Angptl7 injection showed significantly longer survival time than other groups after FLT or BMT. (C-F) The frequency of GFP⁺c-Kit⁺ leukemia blast cells was decreased in the BM, spleen, and peripheral blood (PB) of Id1^−/− recipients without Angptl7 injection after FLT and BMT (n = 8). (G-H) Id1^−/− recipients without Angptl7 injection showed a decrease in the frequency of L-GMP cells in the BM after BMT (n = 8). ∗P < .05; ∗∗P < .01; ∗∗∗P < .005; and ∗∗∗∗P < .001.